182 related articles for article (PubMed ID: 32820577)
1. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
Chaudhary SP; Kwak EL; Hwang KL; Lennerz JK; Corcoran RB; Heist RS; Russo AL; Parikh A; Borger DR; Blaszkowsky LS; Faris JE; Murphy JE; Azzoli CG; Roeland EJ; Goyal L; Allen J; Mullen JT; Ryan DP; Iafrate AJ; Klempner SJ; Clark JW; Hong TS
Oncologist; 2020 Nov; 25(11):e1691-e1700. PubMed ID: 32820577
[TBL] [Abstract][Full Text] [Related]
2. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak EL; Ahronian LG; Siravegna G; Mussolin B; Borger DR; Godfrey JT; Jessop NA; Clark JW; Blaszkowsky LS; Ryan DP; Lennerz JK; Iafrate AJ; Bardelli A; Hong TS; Corcoran RB
Cancer Discov; 2015 Dec; 5(12):1271-81. PubMed ID: 26432108
[TBL] [Abstract][Full Text] [Related]
3. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
4. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
Peng Z; Li Z; Gao J; Lu M; Gong J; Tang ET; Oliner KS; Hei YJ; Zhou H; Shen L
Mol Cancer Ther; 2015 Nov; 14(11):2634-41. PubMed ID: 26330547
[TBL] [Abstract][Full Text] [Related]
5. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
Gordon MA; Gundacker HM; Benedetti J; Macdonald JS; Baranda JC; Levin WJ; Blanke CD; Elatre W; Weng P; Zhou JY; Lenz HJ; Press MF
Ann Oncol; 2013 Jul; 24(7):1754-1761. PubMed ID: 23524864
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
7. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
8.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
9. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
[TBL] [Abstract][Full Text] [Related]
10. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
[TBL] [Abstract][Full Text] [Related]
11. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
[TBL] [Abstract][Full Text] [Related]
12. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
14. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
[TBL] [Abstract][Full Text] [Related]
15. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL; de Melo Gagliato D; Falchook GS; Janku F; Zinner R; Wheler JJ; Subbiah V; Piha-Paul SA; Fu S; Murphy MB; Ajani J; Tang C; Hess K; Hamilton SR; Roy-Chowdhuri S; Kurzrock R; Meric-Bernstam F; Hong DS
Oncotarget; 2014 Apr; 5(7):1837-45. PubMed ID: 24742823
[TBL] [Abstract][Full Text] [Related]
16. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
Berezowska S; Novotny A; Bauer K; Feuchtinger A; Slotta-Huspenina J; Becker K; Langer R; Walch A
PLoS One; 2013; 8(7):e69098. PubMed ID: 23874879
[TBL] [Abstract][Full Text] [Related]
17. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
19. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
[TBL] [Abstract][Full Text] [Related]
20. Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients.
Wang Y; Jiang Z; Xu C; Wang H; Tan L; Su J; Wang X; Jiang D; Hou Y; Song Q
BMC Cancer; 2019 Mar; 19(1):240. PubMed ID: 30885149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]